Iohexol

Generic Name
Iohexol
Brand Names
Omnipaque, Oraltag
Drug Type
Small Molecule
Chemical Formula
C19H26I3N3O9
CAS Number
66108-95-0
Unique Ingredient Identifier
4419T9MX03
Background

Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Indication

Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

Phase 3
Completed
Conditions
Acute Circulatory Failure
Interventions
Drug: Iohexol
First Posted Date
2014-01-30
Last Posted Date
2016-10-25
Lead Sponsor
University Hospital, Tours
Target Recruit Count
100
Registration Number
NCT02050269
Locations
🇫🇷

Service de Réanimation Polyvalente, CHRU de Tours, Tours, France

🇫🇷

University Hospital Strasbourg, Strasbourg, France

🇫🇷

Hospital La SOURCE, Orleans, France

Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization

First Posted Date
2013-11-14
Last Posted Date
2013-11-15
Lead Sponsor
Centro Cardiológico del Caribe, Columbia
Target Recruit Count
220
Registration Number
NCT01984411
Locations
🇨🇴

Clinica General del Norte, Barranquilla, Atlco, Colombia

A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease

Phase 1
Terminated
Conditions
Fabry Disease
Interventions
Drug: Iohexol
First Posted Date
2013-04-25
Last Posted Date
2020-12-16
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
39
Registration Number
NCT01839526
Locations
🇺🇸

Investigational Site Number 840010, La Jolla, California, United States

🇨🇦

Investigational Site Number 124001, Montreal, Canada

🇨🇦

Investigational Site Number 124004, Toronto, Canada

and more 19 locations

Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance

Completed
Conditions
Renal Insufficiency
Renal Disease
Interventions
Drug: Iohexol
First Posted Date
2012-03-06
Last Posted Date
2017-01-04
Lead Sponsor
University of Washington
Target Recruit Count
54
Registration Number
NCT01545531
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Terminated
Conditions
Pancreatic Cancer
First Posted Date
2011-03-30
Last Posted Date
2016-07-01
Lead Sponsor
Stanford University
Target Recruit Count
6
Registration Number
NCT01326364
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

First Posted Date
2010-08-25
Last Posted Date
2018-04-17
Lead Sponsor
Stanford University
Target Recruit Count
12
Registration Number
NCT01188486
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Gastroview
Drug: Omnipaque
First Posted Date
2007-05-25
Last Posted Date
2017-04-18
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
300
Registration Number
NCT00478556
Locations
🇺🇸

The Kirklin Clinic, Birmingham, Alabama, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy